GlassScriptPhysician profile
Lindsey E Mccray
NPI 1972986586
$6,564.22
in general payments reported to CMS, 2019-2025
22 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $946 · 2022: $1,398 · 2023: $1,852 · 2024: $1,296 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,220.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $860.13 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $830.38 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $711.10 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $685.03 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $560.46 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $514.17 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $446.60 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $404.98 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Corium, LLC | $381.43 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $222.19 | 2021-2025 | Hetlioz, Fanapt |
| Alkermes, INC. | $205.24 | 2021-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $201.96 | 2022-2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $191.21 | 2021-2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $79.13 | 2024 | |
| Tris Pharma INC | $62.82 | 2021-2025 | Dyanavel Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $52.41 | 2021 | |
| Adlon Therapeutics L.P. | $44.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $33.35 | 2024 | Cobenfy |
| Jazz Pharmaceuticals INC. | $25.41 | 2022 | |
| Alfasigma USA, INC. | $21.77 | 2021 | |
| Almatica Pharma LLC | $17.63 | 2023 | Loreev Xr |
| Eisai INC. | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Mccray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.